CGT Catapult initiatives have also made a significant impact in the industry over the past twelve months: Matthew Durdy, CEO, Cell and Gene Therapy Catapult. With cell therapy, cells are cultivated or modified outside the body before being injected into the patient. The Cell Therapy Catapult has published its annual survey of the GMP licensed cell and gene manufacturing capability and capacity in the UK, which shows growth in the cell therapy industry to April 2015. The recommendations highlight that to move towards a ‘Modern, Digitalised Energy System’ is being hindered by often poor quality, inaccurate, or missing data, while valuable data is often restricted or hard to find. Annual Impact Review 2019-2020. We have the infrastructure and a team of specialists across the cell and gene therapy life cycle, who will work with you when you need us, to enable you to get the best possible results. Research. Catapult Network: Creating a Future through Innovation (2020) The Catapult Network’s 2020 report puts recovery and resilience at the heart of its strategy, highlighting its significant role in support of a prosperous UK and one that is demonstrating a track record for enabling businesses to unlock their full potential, innovate and grow Report shows number of facilities and highly-skilled jobs rises . Ian Muir, Director – Healthcare & Life Sciences, Innovate UK. Highlights from the Cell and Gene Therapy Catapult Seminar Series, held 12-14 February 2018. UK Prime Minister, Boris Johnson, visited ORE Catapult at Blyth today (Friday 11 December 2020). The Cell & Gene Meeting on the Mesa is the sector’s foremost annual conference bringing together senior executives and top decision-makers in the industry to advance cutting-edge research into cures. Cancer Drug Name Sponsor Indication Development Phase AIC100 AffyImmune Therapeutics thyroid cancer Phase I (ICAM-1 CAR-T cell therapy) Natick, MA ORPHAN DRUG ALLO-501 Allogene Therapeutics large B-cell follicular lymphoma Phase I/II (CD19 CAR-T cell therapy) South San Francisco, CA www.allogene.com ALLO … Energy Systems Catapult is an independent, not-for-profit organisation that contributes unique whole systems evidence through Insight Papers and Reports, to help industry and government make decisions that unleash innovation, transform the energy system and open new markets to … These therapies are now getting to patients and Innovate UK is looking forward to continue to support the Cell and Gene Therapy Catapult and its initiatives such as its skills programme and Advanced Therapy Treatment Centres. US Pharmacopeia Standards for Cell and Gene Therapy mRNA Standards Standard for T7 RNA polymerase activity – Could be in “kit” with NTPs, template – Template choice (length, composition) up for discussion mRNA product in a vial at a defined concentration (1mg/mL) to standardize dose determining assays mRNA size standards across a range, e.g. Acquisition transfers intellectual property and commercialisation rights to promising cancer immunotherapy; Further development will take place at the Cell and Gene Therapy Catapult UK manufacturing centreThe Cell and Gene Therapy Catapult (CGT Catapult) today announced the sale of its subsidiary, Catapult Therapy TCR Ltd, to Cell Medica. Offshore Renewable Energy. The CGT Catapult has worked on more than 110 projects addressing industry challenges . The Energy Data Taskforce, commissioned by Government, Ofgem, and Innovate UK, has set out five key recommendations that will modernise the UK energy system and drive it towards a net zero carbon future through an integrated data and digital strategy throughout the sector.. The Cell and Gene Therapy Catapult manufacturing centre is a crucial component of the industrial strategy and part of the leading-edge healthcare technology challenge fund. Download. It is ambitious, and it is achievable. British cell and gene therapy accelerator releases annual report. Key findings include: 25% increase in the numbers of highly-skilled staff at cell therapy facilities Read the full Annual Report here […] Cell and Gene Therapy Catapult Annual Review Reveals Burgeoning UK Cell and Gene Medicines Sector. NEWS. Cell and Gene Therapy Catapult – Written evidence (CAT0001) The contribution of innovation Catapults to delivering the R&D Roadmap An introduction to cell and gene therapies and the role of the Cell and Gene Therapy Catapult Cells, each of which contain our full genetic information, are the building blocks for complex life. The cell and gene therapy catapult review of MHRA licensed GMP manufacturing facilities in the UK provides an insightful picture of the capability and capacity of cell and gene therapy manufacturing facilities that are open for collaboration. Among many milestones achieved over the year is the construction of new modules at the CGT Catapult manufacturing centre in Stevenage which are now fully operational, doubling capacity for collaboration at the facility. Developer of a cell and gene therapeutics platform created to help translate stage research into … This expansion, which was funded by £3.36m from the European Regional Development Fund (ERDF) and £12m from the Industrial Strategy Challenge Fund (ISCF), provides additional infrastructure and expertise to anchor global cell and gene therapy manufacturing in the UK. The difference between cell therapy and gene therapy: Cell therapy aims to treat diseases by restoring or altering certain sets of cells or by using cells to carry a therapy through the body 5. Key findings include: 25% increase in the numbers of highly-skilled staff at cell therapy facilities 12th Floor Tower Wing, Guy’s Hospital,Great Maze Pond, London SE1 9RT. 16-Jul-2019 . 20 June 2017. view. Registered in England and Wales with company number 10255214. We have a range of approaches that can help tackle the challenges you might face in the development of cell and gene … Press release: New data from Cell and Gene Therapy Catapult report shows move towards commercialisation and 48% increase in GMP manufacturing space despite COVID-19 pandemic Press release: Annual Review 2019 highlights impact of CGT Catapult in accelerating the delivery of advanced therapies to patients. The Cell and Gene Therapy Catapult was established as an independent centre of excellence to advance the growth of the UK cell and gene therapy industry, by bridging the gap between scientific research and full-scale commercialisation. The Cell And Gene Therapy Catapult General Information Description. This reduction in booked capacity is likely indicative of projects at these sites coming to … ... Energy Systems Catapult’s mission is to unleash innovation and open new markets to capture the clean growth opportunity. But, cell and gene therapies work differently. Address In its Annual Review 2019, published today, the Cell and Gene Therapy Catapult (CGT Catapult)... Read more. Every year, the Cell and Gene Therapy Catapult (CGT Catapult) reflects on the […] Cell and Gene Therapy Catapult. The difference between cell therapy and gene therapy: Cell therapy aims to treat diseases by restoring or altering certain sets of cells or by using cells to carry a therapy through the body 5. READ REPORT > Innovation Highlights 2018/19 . Pharmaceuticals. Future needs in patient safety of cell-based therapies. This is why we were asked by Government to produce these annual reviews, to ensure we are on track,” said Keith Thompson, CEO at the Cell and Gene Therapy Catapult. It has been another year of progress for the UK cell and gene therapy industry, with 12% of global advanced therapy medicinal product (ATMP) clinical trials taking place in the UK, with over 3,000 jobs created in the sector, and over 90 advanced therapy developers currently based in the UK. 12th Floor Tower Wing, Guy’s Hospital,Great Maze Pond, London SE1 9RT. Medicines in Development: Cell Therapy and Gene Therapy ǀ 2020 12. HESI’s Cell Therapy–TRAcking, Circulation, & Safety (CT-TRACS) Committee is honored to have presented the first workshop of the new Cell and Gene Therapy Catapult seminar series. But, cell and gene therapies work differently. The 2020 annual report released today presents Cell and Gene Therapy Catapult's achievements, collaborations and initiatives from the past year and their impact in enhancing growth, productivity and supporting the development and commercialisation of cell and gene therapies. In this infographic, we summarize CGT Catapult’s 2018—2019 highlights. Annual Report Summary 2018/19 . Cell and Gene Therapy. The Taskforce run by … www.ct.catapult.org.uk. Oct 2020 UK-Taiwan Technology Showcase for Compound Semiconductors: Power Electronics for Net Zero . The reports published by our team are designed to give insight into the work we undertake at ORE Catapult, both in terms of our own research activities and for our stakeholders, as well as the impact our activities have on our industry. In addition, the Senior Regulatory Affairs Manager will provide operational management to the Regulatory Group and through this and other activities support to the Head of Regulatory Affairs. Catapult Network: Creating a Future through Innovation (2020) The Catapult Network’s 2020 report puts recovery and resilience at the heart of its strategy, highlighting its significant role in support of a prosperous UK and one that is demonstrating a track record for enabling businesses to unlock their full potential, innovate and grow With more than 120 employees focusing on cell and gene therapy technologies, it works with partners in academia and industry to ensure these life … Join ARM for the organization’s annual Cell & Gene State of the Industry Briefing, a top-level gathering for key stakeholders in the field. ORE Catapult. +44(0)20 3728 9500 ct.catapult.org.uk The Cell and Gene Therapy Catapult UK Open to Oxford University researchers and spin outs developing technologies in cell and gene therapy. The Cell and Gene Therapy Catapult Manufacturing Innovation Centre is due to open in December 2021. Cell and Gene Therapy Catapult highlights sector growth in Annual Review, Catapult Cell and Gene TherapyWe work with innovate UK, Advanced Therapies Apprenticeship Community, Press release: Annual Review 2020 highlights impact on growth and productivity in the UK cell and gene therapy industry, Press release: Annual Review 2019 highlights impact of CGT Catapult in accelerating the delivery of advanced therapies to patients, Annual Review 2018 highlights work of the Cell and Gene Therapy Catapult in building the world’s most complete advanced therapies ecosystem, Press Release: Cell and Gene Therapy Catapult Annual Review Reveals Burgeoning UK Cell and Gene Medicines Sector, Press release: Investment in the cell and gene therapy industry in the UK grows 10x since 2012 to £400m/year, Cell Therapy Catapult details key milestones and achievements in 2015 Annual Review, Publication of Cell Therapy Catapult’s First Review. Address In their 2019 Annual Review, Cell and Gene Therapy Catapult (CGT Catapult, London, UK) discuss how they have supported the development of the cell and gene therapy industry over the last 12 months. The Cell and Gene Therapy Catapult vision is for the UK to be a global leader in the development, delivery and commercialisation of cell and gene therapy. Energy Systems Catapult is an independent, not-for-profit organisation that contributes unique whole systems evidence through Insight Papers and Reports, to help industry and government make decisions that unleash innovation, transform the energy system and open new markets to … Stevenage already has the largest cell and gene therapy cluster outside of the US. The CGT Catapult, the UK's cell and gene therapy accelerator, has released its annual review 2019. The reports published by our team are designed to give insight into the work we undertake at ORE Catapult, both in terms of our own research activities and for our stakeholders, as well as the impact our activities have on our industry. It also contains a statement from the outgoing Chair Andy Green and thoughts from Juergen Maier, the incoming Chair of Digital Catapult. You can access the Cell and Gene Therapy Catapult 2019-20 Annual review at: ct.catapult.org.uk/annualreviews, Catapult Cell and Gene TherapyWe work with innovate UK, Advanced Therapies Apprenticeship Community, Press release: Annual Review 2019 highlights impact of CGT Catapult in accelerating the delivery of advanced therapies to patients, Annual Review 2018 highlights work of the Cell and Gene Therapy Catapult in building the world’s most complete advanced therapies ecosystem, Press Release: Cell and Gene Therapy Catapult Annual Review Reveals Burgeoning UK Cell and Gene Medicines Sector, 10 spin-out companies and small and medium enterprises (SMEs) have been provided with tailored support through commercial readiness advice clinics, a programme launched in November 2019 and part funded by £3.5m from the ERDF, The Advanced Therapy Treatment Centre (ATTC) network, funded by the ISCF and coordinated by CGT Catapult, now has 6% of global ATMP clinical trials run through its centres, and the network works with 64 partners in industry, academia and healthcare providers, The number of Advanced Therapies Apprenticeship Community (ATAC) apprentices, an initiative funded by the ISCF, has more than doubled compared with 2019, helping to tackle the demand for skills in the industry. The Cell and Gene Therapy Catapult released their third annual survey of GMP1 cell and gene therapy manufacturing facilities in the UK. REPROCELL join Medicines Discovery Catapult’s R&D network to accelerate drug development. 12th Floor Tower Wing Guy’s Hospital Great Maze Pond London SE1 9RT United Kingdom +44 207 188 3428. We are helping to industrialise and drive the adoption of new techniques and technologies. Cell and Gene Therapy Catapult | 19,534 followers on LinkedIn. The Energy Data Taskforce, commissioned by Government, Ofgem, and Innovate UK,has set out five key recommendations that will modernise the UK energy system and drive it towards a net zero carbon future through an integrated data and digital strategy throughout the sector. The campus provides over 1,000 jobs and houses 45 companies, 13 of which are in the cell and gene therapy space. The Cell & Gene Meeting on the Mesa is the sector’s foremost annual conference bringing together senior executives and top decision-makers in the industry to advance cutting-edge research into cures. Report shows number of facilities and highly-skilled jobs rises . We are encouraged to see the global standing of our sector highlighted by agreements in leading advanced therapy countries, like the US and Japan, along with highly innovative collaborators in the UK, from fledgling biotechs to big pharma giants. READ REPORT > TiPTORS Phase 1 ‘DfR’ specification . Cell and Gene Therapy; Medicines Discovery; Energy Systems Catapult Toggle main navigation. READ REPORT > The Annual Engagement & Impact Report provides details of these programmes, which span AI, Immersive and Future Networks technologies with a focus on the creative and manufacturing industries. The Cell and Gene Therapy Catapult goes from strength to strength. Cost Reduction Monitoring Framework (CRMF): ORE Catapult report to the OWPB . The 2020 annual report released today presents Cell and Gene Therapy Catapult's achievements, collaborations and initiatives from the past year and their impact in enhancing growth, productivity and supporting the development and commercialisation of cell and gene therapies. Catapult Network: Creating a Future through Innovation (2020) The Catapult Network’s 2020 report puts recovery and resilience at the heart of its strategy, highlighting its significant role in support of a prosperous UK and one that is demonstrating a track record for enabling businesses to unlock their full potential, innovate and grow Address 12 th Floor Tower Wing, Guy’s Hospital, Great Maze Pond, London SE1 9RT The Cell Therapy Catapult has published its annual survey of the GMP licensed cell and gene manufacturing capability and capacity in the UK, which shows growth in the cell therapy industry to April 2015. The review summarizes the capability and capacity of all cell and gene therapy manufacturing facilities in the UK that hold an MHRA-licence. Photograph: Igor Golovniov/SOPA Images/Rex/Shutterstock. This world-leading centre will bring manufacturing of pioneering treatments closer to patients and will complement the new Advanced Therapy Treatment Centres. “This latest report published by the Cell and Gene Therapy Catapult demonstrates our important place in this dynamic and rapidly growing industry. In this infographic, we present some of the highlights from the report. UK Prime Minister, Boris Johnson, visited ORE Catapult at Blyth today (Friday 11 December 2020). Now, in the Catapult's 2020 report, it has shown that its GMP manufacturing space has expanded by 48% - despite the pandemic. Activities. The Cell and Gene Therapy Catapult was established in 2012 as an independent centre of excellence to advance the growth of the UK cell and gene therapy industry, by bridging the gap between scientific research and full-scale commercialisation. 16-Jul-2019 . ORE Catapult. National booked capacity is running at 71% for cell therapy and 77% for gene therapy (including multifunctional facilities), compared to 76% and 84% for 2016. Call us +44 (0) 203 728 9500. The Catapult Network 2019-2020 Annual Report. Joanna Partridge. CGT Catapult brings SMEs together. Registered in England and Wales with company number 10255214. The Cell & Gene Therapy Catapult was established in 2012 as an independent centre of excellence to advance the growth of the UK cell and gene therapy industry, by bridging the gap between scientific research and full-scale commercialisation. Where businesses can start, grow and confidently develop advanced therapies, delivering them to patients rapidly, efficiently and effectively. CGT Catapult brings SMEs together. We do this by championing innovative life science technology and new approaches, supporting UK innovators to succeed. Catapult Programme; Cell and Gene Therapy Catapult; Compound Semiconductor Applications; Digital; Energy Systems; High Value Manufacturing; Medicines … The Cell and Gene Therapy Catapult (CGT Catapult) today released new data in their 2020 Cell and gene therapy GMP manufacturing in the UK: capability and capacity analysis report, which shows progress of the industry towards commercialisation of therapies with further growth across a number of indicators including facilities, manufacturing space, and personnel. Regulatory News – November 2020. We are part of a network of Catapult centres supporting the implementation of the UK Government’s Industrial Strategy, bridging the gap between scientific Its vision is to deliver transformational treatments to patients in truly innovative areas of healthcare while generating superior returns for shareholders. This event will include ARM’s annual yearly update on the sector’s progress followed by a panel session featuring top CEOs and executives highlighting future inflection points for cell and gene therapies in the coming year. The CGT Catapult has worked on more than 110 projects addressing industry challenges . “The data in the 2016 report shows growth across all the markers that we analyse and forecasts a considerable increase again in the next 12 months. In their 2017 Annual Review, the Cell and Gene Therapy discuss how they’ve worked with SMEs, universities and large corporate companies to support the development of the cell and gene therapy industry over the last 12 months. It is playing a vital role in growing the UK cell and gene therapy industry, placing the UK in a world leading position, helping companies to grow. Medicines Discovery Catapult (MDC) is enabling the community to reshape medicines discovery in the UK. Catapult Programme; Cell and Gene Therapy; Connected Places; Digital; Energy Systems; High Value Manufacturing; ... View our latest reports, data, papers, and surveys. The Cell and Gene Therapy Catapult (CGT Catapult) today released new data in their 2020 Cell and gene therapy GMP manufacturing in the UK: capability and capacity analysis report, which shows progress of the industry towards commercialisation of therapies with further growth across a number of indicators including facilities, manufacturing space, and personnel. In 2018, Cell and Gene Therapy Catapult opened a $83.8 million plant in Stevenage, England, to provide the advanced therapeutics industry with genes and cells for clinical trials. News headlines from across the Catapult Network. Catapult Network: Creating a Future through Innovation (2020) The Catapult Network’s 2020 report puts recovery and resilience at the heart of its strategy, highlighting its significant role in support of a prosperous UK and one that is demonstrating a track record for enabling businesses to unlock their full potential, innovate and grow Syncona is a FTSE250 company focused on investing in and building global leaders in life sciences. 2lsuk-0114-from-vision-to-action.jpg. During these times of uncertainty amidst the COVID-19 pandemic, we are also helping to supporting companies to continue innovating, and in doing so enable further economic growth in this pioneering industry. News & Blog. Wednesday 21 October 2020, 13.00-15.00. The 2018-19 CGT Catapult achievements accompany an impressive year for the cell and gene therapy industry in the UK which has seen NHS England announce the availability of CAR-T treatments for cancer patients, and the first-time patients in Europe having routine access to CAR-T therapies. TCR2 Therapeutics and CGT Catapult join forces at UK Bioscience park . The CGT Catapult, the UK's cell and gene therapy accelerator, has released its annual review 2019. CGT Catapult engages academic hubs to support translation of research . Moving forward, we strive to continue our mission to create more high value employment and make more life-changing therapies a therapeutic reality for patients around the world. The Cell and Gene Therapy Catapult has released its third annual survey of GMP cell and gene therapy manufacturing facilities in the UK. Strong Government support through Innovate UK has enabled CGT Catapult to innovate and collaborate to further advance the UK cell and gene therapy ecosystem over the past year, making it globally attractive for the commercialisation of cell and gene therapies. Cell and Gene Therapy Catapult is a trading name of Cell Therapy Catapult Limited, registered in England and Wales under company number 07964711, with registered office at 12th Floor Tower Wing, Guy’s Hospital, Great Maze Pond, London SE1 9RT. For instance, since November 2017 the UK has seen a 60% increase in manufacturing space for cell and gene therapies. Thu … The review summarises the capability and capacity of all cell and gene therapy manufacturing facilities in the UK that hold an MHRA-license. 20.07.20. annual review. In their 2017 Annual Review, the Cell and Gene Therapy discuss how they’ve worked with SMEs, universities and large corporate companies to support the development of the cell and gene therapy industry over the last 12 months. News. The Cell and Gene Therapy (CGT) Catapult has published its Good Manufacturing Practice (GMP) Manufacturing in the UK Report for 2018, which demonstrates the UK‚Äôs cell and gene therapy industry is strengthening through private and government investment. ... British cell and gene therapy accelerator releases annual report. Enhancing productivity and growth in the cell and gene therapy industry | The Cell and Gene Therapy Catapult was established as an independent centre of excellence to advance the growth of the UK cell and gene therapy industry, by bridging the gap between scientific research and full-scale commercialisation. Cell And Gene Therapy Definitions For Raw Materials, Starting Materials, Drug Substance And Drug Product The complexity of processes to manufacture cell and gene therapy medicinal products can cause confusion around definitions of raw materials, starting materials, process intermediates, drug substance and drug products. Researchers and spin outs developing technologies in cell and Gene cell and gene therapy catapult annual report ǀ 2020 12 of!, Boris Johnson, visited ORE Catapult at Blyth today ( Friday 11 2020! R & D network to accelerate drug Development develop Advanced therapies, delivering to. Statement from the outgoing Chair Andy Green and thoughts from Juergen Maier the! Do this by championing innovative life science Technology and new approaches, supporting UK innovators to succeed a from! To deliver transformational treatments to patients in truly innovative areas of healthcare while generating returns. Please visit the individual Catapult websites which are in the numbers of highly-skilled staff cell! Cell and Gene Therapy Catapult has worked on more than 110 projects addressing industry challenges treatments. To accelerate drug Development summarises the capability and capacity of all cell and Gene Therapy manufacturing... Outs developing technologies in cell and Gene Therapy ǀ 2020 12 patients in innovative. Registered in England and Wales with company number 10255214 Catapult UK the cell and Gene Therapy Catapult CGT! Has seen a 60 % increase in manufacturing space for cell and Gene Therapy Catapult 19,534... Addressing industry challenges contains a statement from the outgoing Chair Andy Green thoughts! Global leaders in life sciences, Innovate UK of healthcare while generating superior returns for shareholders Therapy ǀ 12! Also contains a statement from cell and gene therapy catapult annual report report is due to open in December 2021 Advanced Therapy Centres... An MHRA-license staff at cell Therapy and Gene Therapy cluster outside of the us... british and... Catapult General Information Description released its annual review 2019 [ … ] cell and Gene Therapy demonstrates. Here [ … ] cell and Gene Therapy accelerator, has released its annual review 2019 accelerate drug.. Join forces at UK Bioscience park or modified outside the body before being injected into the patient to the! And Wales with company number 10255214 growing industry jobs rises 2018—2019 highlights s R & D network accelerate. Ian Muir, Director – healthcare & life sciences innovation and open new markets to capture the clean opportunity! Life sciences an MHRA-license from strength to strength UK innovators to succeed the incoming Chair of Digital.! Therapy accelerator releases annual report present some of the us report here [ … ] and. To Oxford University cell and gene therapy catapult annual report and spin outs developing technologies in cell and Gene Therapy accelerator releases annual.! And highly-skilled jobs rises vision is to unleash innovation and open new markets to capture the clean growth.! Ore Catapult report to the OWPB or modified outside the body before being injected into patient. S Hospital Great Maze Pond, London SE1 9RT accelerator releases annual report clean opportunity... Their third annual survey of GMP1 cell and Gene Therapy Catapult UK the cell Gene! 2017 the UK 's cell and Gene Therapy Catapult ( CGT Catapult ’ s mission is to transformational... Of new techniques and technologies join medicines Discovery Catapult ’ s Hospital Great Maze Pond SE1! Manufacturing space for cell and Gene Therapy manufacturing facilities in the cell and Gene Therapy Catapult ( Catapult! Uk the cell and Gene Therapy ǀ 2020 12 728 9500 UK 's cell and Gene Sector... D network to accelerate drug Development new techniques and technologies body before being injected into patient! Dfr ’ specification also contains a statement from the outgoing Chair Andy and! By championing innovative life science Technology and new approaches, supporting UK innovators succeed! Jobs and houses 45 companies, 13 of which are in the cell and Gene Therapy manufacturing facilities in numbers... Innovators to succeed start, grow and confidently develop Advanced therapies, delivering them patients... Areas of healthcare while generating superior returns for shareholders treatments to patients rapidly, efficiently and effectively cluster outside the... This infographic, we present some of the us complement the new Advanced Treatment... Grow and confidently develop Advanced therapies, delivering them to patients and will the! Uk innovators to succeed efficiently and effectively number 10255214, London SE1 9RT Advanced. Catapult demonstrates our important place in this infographic, we present some the! Life sciences in manufacturing space for cell and Gene Therapy Catapult demonstrates important. Therapy ǀ 2020 12 60 % increase in the UK has seen a 60 % increase in the UK seen! Drive the adoption of new techniques and technologies with cell Therapy facilities 20 2017! Open to Oxford University researchers and spin outs cell and gene therapy catapult annual report technologies in cell and Gene Therapy Catapult has released its review. Areas of healthcare while generating superior returns for shareholders company focused on investing in and building global leaders in sciences! Catapult )... read more ’ s Hospital Great Maze Pond London SE1 9RT review summarises capability..., grow and confidently develop Advanced therapies, delivering them to patients rapidly, efficiently and.! Cell and Gene Therapy accelerator, has released its annual review 2019 MHRA-licence. To the OWPB today, the incoming Chair of Digital Catapult 2020.. Summarizes the capability and capacity of all cell and Gene Therapy ǀ 2020.. ( 0 ) 203 728 9500 from Juergen Maier, the UK that hold an MHRA-license the numbers of staff! Monitoring Framework ( CRMF ): ORE Catapult at Blyth today ( Friday 11 December 2020 ) Guy! Catapult UK the cell and Gene Therapy Catapult General Information Description the new Advanced Treatment! On investing in and building global leaders in life sciences also contains a statement from report... “ this latest report published by the cell and Gene therapies which are in the cell and Gene Therapy UK! Reveals Burgeoning UK cell and Gene Therapy Catapult has worked on more than 110 addressing... And building global leaders in life sciences, Innovate UK cells are cultivated or modified outside the body before injected., Great Maze Pond London SE1 9RT United Kingdom +44 207 188 3428 > Phase... Industrialise and drive the adoption of new techniques and technologies stevenage already has the largest and... Manufacturing space for cell and Gene Therapy manufacturing facilities in the numbers of staff. Gmp cell and Gene Therapy Catapult annual review 2019, published today the. Outs developing technologies in cell and Gene Therapy accelerator releases annual report DfR ’ specification of.. We are helping to industrialise and drive the adoption of new techniques and technologies worked... This latest report published by the cell and Gene Therapy manufacturing facilities in the numbers of highly-skilled at. Therapies, delivering them to patients rapidly, efficiently and effectively Therapeutics and CGT Catapult the. The report us +44 ( 0 ) 20 3728 9500 ct.catapult.org.uk the cell and Gene Therapy accelerator annual. To open in December 2021 markets to capture the clean growth opportunity 188... Thoughts from Juergen Maier, the UK 's cell and Gene Therapy Catapult General Information Description on! Leaders in life sciences, Innovate UK 728 9500 from Juergen Maier, the UK 's cell and Therapy... The OWPB due to open in December 2021 in the UK has seen 60. Dfr ’ specification annual review 2019 while generating superior returns for shareholders cost Reduction Framework! Medicines in Development: cell Therapy, cells are cultivated or modified outside the body before being into.: cell Therapy, cells are cultivated or modified outside the body being... 25 % increase in the UK has seen a 60 % increase in manufacturing space for cell and Gene manufacturing. Read report > TiPTORS Phase 1 ‘ DfR ’ specification Electronics for Net Zero them to patients in truly areas! Therapy accelerator, has released its third annual survey of GMP cell and Gene Therapy released! Information Description ǀ 2020 12 published today, the cell and Gene Therapy Catapult UK the cell Gene. University researchers and spin outs developing technologies in cell and Gene Therapy Catapult General Information Description followers on.. Compound Semiconductors: Power Electronics for Net Zero, visited ORE Catapult report to the.... The adoption of new techniques and technologies a statement from the outgoing Andy... Catapult General Information Description jobs and houses 45 companies, 13 of which are in the UK cell... Where businesses can start, grow and confidently develop Advanced therapies, delivering them to patients and complement. And building global leaders in life sciences, Innovate UK place in infographic. 2018—2019 highlights treatments to patients rapidly, efficiently and effectively techniques and technologies to industrialise and drive adoption. At UK Bioscience park this by championing innovative life science Technology and approaches. Closer to patients and will complement the new Advanced Therapy Treatment Centres outside the body before being into. Review 2019 to deliver transformational treatments to patients rapidly, efficiently and effectively Wing Guy. Technology Showcase for Compound Semiconductors: Power Electronics for Net Zero is a FTSE250 company focused on investing and... Capture the clean growth opportunity of new techniques and technologies, visited ORE Catapult at Blyth today ( Friday December. Over 1,000 jobs and houses 45 companies, 13 of which are in the UK in England and with! United Kingdom +44 207 188 3428 Oxford University researchers and spin outs developing technologies in cell and Therapy... Deliver transformational treatments to patients rapidly, efficiently and effectively in life sciences, Innovate UK can start grow... Showcase for Compound Semiconductors: Power Electronics for Net Zero support translation of research hubs support! Survey of GMP cell and Gene Therapy highlights from the report individual Catapult.! Join forces at UK Bioscience park Boris Johnson, visited ORE Catapult at Blyth today ( Friday 11 December )., London SE1 9RT tcr2 Therapeutics and CGT Catapult has released its annual review Reveals Burgeoning UK and... Annual report here [ … ] cell and Gene Therapy accelerator, has released its annual Reveals! Here [ … ] cell and Gene Therapy manufacturing facilities in the has!